Dr. Scandling is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Dr
Palo Alto, CA 94305Phone+1 650-725-9891- Is this information wrong?
Education & Training
- University of RochesterFellowship, Nephrology, 1981 - 1982
- West Virginia UniversityResidency, Internal Medicine, 1978 - 1981
- Virginia Commonwealth University School of MedicineClass of 1978
Certifications & Licensure
- NV State Medical License 2019 - 2025
- CA State Medical License 1989 - 2024
- VA State Medical License 1984 - 2002
- NY State Medical License 1981 - 1997
- WV State Medical License 1979 - 1995
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM) Start of enrollment: 2005 Jun 01
- Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs Start of enrollment: 2004 Jul 01
- Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs. Start of enrollment: 2010 Jul 14
Publications & Presentations
PubMed
- 1 citationsPegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label PROTECT clinical trial.Abdul Abdellatif, Lin Zhao, Jason Chamberlain, Katya Cherny, Yan Xin, Brad A Marder, John D Scandling, Kenneth Saag> ;Clinical Transplantation. 2023 Sep 1
- 5 citationsTrends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017.Xingxing S Cheng, Jialin Han, Jennifer L Braggs-Gresham, Philip J Held, Stephan Busque, John P Roberts, Jane C Tan, John D Scandling, Glenn M Chertow, Avi Dor> ;JAMA Network Open. 2022 Mar 1
- 13 citationsSARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.Aileen X Wang, Stephan Busque, Jamie Kuo, Upinder Singh, Katharina Röeltgen, Benjamin A Pinsky, Glenn M Chertow, John D Scandling, Colin R Lenihan> ;Kidney360. 2022 Jan 27
- Join now to see all
Journal Articles
- Review Macrochimerism and Clinical Transplant ToleranceSamuel Strober, Stephan Busque, Edgar Engleman, Robert Lowsky, John D Scandling, Judith Shizuru, ScienceDirect
Press Mentions
- Stanford Team Prevents Kidney Transplant Rejection Without DrugsApril 24th, 2002
Grant Support
- Cyclosporine &Neoral In Post Renal Allograft RecipientsNational Center For Research Resources1999–2001
Hospital Affiliations
- Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: